Doses to pelvic bone marrow from intracavitary brachytherapy in carcinoma cervix: A dosimetric study
Open Access
- 1 January 2026
- journal article
- Published by Wolters Kluwer Health in Journal of Cancer Research and Therapeutics
- Vol. 22 (1) , 84-89
Abstract
Purpose: Current dose–volume constraints for pelvic bone marrow (PBM) sparing in radiotherapy for locally advanced cervical carcinoma (LACC) typically do not account for the dose contribution from intracavitary brachytherapy (ICBT). This study aimed to quantify the radiation dose received by PBM during ICBT. Materials and Methods: This dosimetric analysis utilized computed tomography (CT) data from 15 patients with LACC treated with ICBT. Each patient received 3 weekly fractions of 7 Gy. PBM was delineated from the sacrum to the ischial tuberosities across all 45 CT sessions (three per patient). Two treatment plans were generated—Plan A (high-risk clinical target volume [HR-CTV]–based) and Plan B (Point A–based)—yielding 90 plans in total. PBM volumes receiving ≥1.5 Gy (V1.5), 1 Gy (V1), 0.75 Gy (V0.75), and 0.5 Gy (V0.5) were recorded. Results: Out of 15 patients, 9 were diagnosed with stage IIB and 6 with stage IIIB (FIGO 2018). The median HR-CTV volume was 19.2 cc (range: 17–35.8 cc), with a median D90 per fraction of 6.9 Gy. The median PBM volume was 927.5 cc (range: 620.8–999.3 cc). For Plan A, the median V1.5, V1, V0.75, and V0.5 were 2.7%, 13%, 24.98%, and 53.69%, respectively, compared to 3.89%, 21.82%, 40.3%, and 67.36% for Plan B. Mean values for Plan A vs. Plan B were as follows: V1.5 (2.89% ±2.6% vs. 5.15% ± 3.57%, P = 0.058), V1 (14.14% ±9.67% vs. 20.6% ±7.82%, P = 0.054), V0.75 (29.22% ±14.99% vs. 39.47% ±11.36%, P = 0.045), and V0.5 (53.2% ±17.1% vs. 64.39% ±12.33%, P = 0.049). Conclusion: ICBT contributes a measurable dose to the PBM, with approximately 15–20% of PBM receiving around 1 Gy per 7 Gy fraction.Keywords
This publication has 18 references indexed in Scilit:
- Positron Emission Tomography-Guided Bone Marrow-Sparing Radiation Therapy for Locoregionally Advanced Cervix Cancer: Final Results From the INTERTECC Phase II/III TrialInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2022
- Correlations between bone marrow radiation dose and hematologic toxicity in locally advanced cervical cancer patients receiving chemoradiation with cisplatin: a systematic reviewRadiotherapy and Oncology, 2021
- Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort studyRadiotherapy and Oncology, 2016
- Hematopoietic Stem Cell and Its Bone Marrow Niche2016
- Hematologic Toxicity in RTOG 0418: A Phase 2 Study of Postoperative IMRT for Gynecologic CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2013
- 3’-deoxy-3’-[18F]fluorothymidine PET Quantification of Bone Marrow Response to Radiation DoseInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Radiation-Related Predictors of Hematologic Toxicity After Concurrent Chemoradiation for Cervical Cancer and Implications for Bone Marrow–Sparing Pelvic IMRTInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Normal Tissue Complication Probability Modeling of Acute Hematologic Toxicity in Cervical Cancer Patients Treated With ChemoradiotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Prospective randomized comparison of monthly fluorouracil and cisplatin versus weekly cisplatin concurrent with pelvic radiotherapy and high-dose rate brachytherapy for locally advanced cervical cancerGynecologic Oncology, 2008
- Computed Tomography Versus Magnetic Resonance Imaging-Based Contouring in Cervical Cancer Brachytherapy: Results of a Prospective Trial and Preliminary Guidelines for Standardized ContoursInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2007